Methylation Pattern of the SOCS3 and IL6R Promoters in Rheumatoid Arthritis
Table 3
Characteristics of patients with rheumatoid arthritis included in the methylation analysis.
Characteristics
High disease activity, n = 30
Remission, n = 22
value
Age (years)
53.6 ± 12.3
48.7 ± 12.7
0.21
Females; n (%)
22 (73.3)
21 (95.5)
0.09
Disease duration (years)
10 [2–16]
9.5 [3.5–16]
0.96
RF-positive; n (%),
23 (76.7)
12 (54.5)
0.17
ACPA-positive; n (%)
29 (96.7)
20 (90.9)
0.78
ESR
54 [28–67]
7 [2–11.5]
<0.0001
CRP (mg/dl)
15.72 [8.54–27.2]
0.45 [0.13–4.09]
<0.0001
VAS PGA
67.5 [52–73]
8 [3–9.5]
<0.0001
VAS PhGA
59 [49–70]
5 [1.5–7]
<0.0001
Treatment:
At least on methotrexate, n (%)
23 (76.7)
15 (68.2)
0.72
At least on biologics, n (%)
7 (23.3)
11 (50)
0.09
At least on steroids, n (%)
23 (76.7)
7 (31.8)
0.003
Single-line therapy, n (%)
4 (13.3)
7 (31.8)
0.2
Methotrexate, n (%)
2 (6.7)
3 (13.6)
0.71
Biologics, n (%)
0
1 (4.5)
0.88
Steroids, n (%)
1 (3.3)
0
0.88
Other cDMARD, n (%)
1 (3.3)
3 (13.6)
0.39
Double-line therapy, n (%)
17 (56.7)
10 (45.5)
0.6
Methotrexate + steroids, n (%)
13 (43.3)
1 (4.5)
0.0051
Methotrexate + biologics, n (%)
2 (6.7)
4 (18.2)
0.4
Steroids + biologics, n (%)
0
1 (4.5)
0.88
Other, n (%)
2 (6.7)
4 (18.2)
0.4
Triple-line therapy, n (%)
9 (30)
5 (22.7)
0.79
Data are presented as mean ± SD, number (percentage), or median [interquartile range]. ACPA, anticitrullinated protein antibodies; CRP, C-reactive protein; cDMARD, classical disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; VAS PhGA, visual analog scale physician global assessments; VAS PGA, visual analog scale patient global assessments.
